Daniel P. Gale

11.7k total citations · 1 hit paper
95 papers, 3.1k citations indexed

About

Daniel P. Gale is a scholar working on Nephrology, Molecular Biology and Genetics. According to data from OpenAlex, Daniel P. Gale has authored 95 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Nephrology, 23 papers in Molecular Biology and 21 papers in Genetics. Recurrent topics in Daniel P. Gale's work include Renal Diseases and Glomerulopathies (46 papers), Complement system in diseases (17 papers) and Platelet Disorders and Treatments (13 papers). Daniel P. Gale is often cited by papers focused on Renal Diseases and Glomerulopathies (46 papers), Complement system in diseases (17 papers) and Platelet Disorders and Treatments (13 papers). Daniel P. Gale collaborates with scholars based in United Kingdom, United States and China. Daniel P. Gale's co-authors include Patrick H. Maxwell, Damien Ashby, Richard Chapman, Mark Busbridge, David Taube, P. Choi, Kevin G. Murphy, Neill Duncan, Frederick W.K. Tam and Matthew C. Pickering and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Daniel P. Gale

85 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Outcomes in IgA Nephropathy

2023 169 citations David Pitcher, Fiona Braddon et al. Clinical Journal of the American Society of Nephrology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel P. Gale United Kingdom	27	1.4k	1.1k	1.0k	740	656	95	3.1k
B. Mougenot France	29	1.2k 0.9×	522 0.5×	307 0.3×	409 0.6×	1.0k 1.6×	67	3.0k
Shinsuke Yasuda Japan	32	299 0.2×	1.1k 0.9×	993 1.0×	199 0.3×	474 0.7×	163	3.2k
Hiroshi Kaito Japan	27	1.1k 0.8×	406 0.4×	187 0.2×	275 0.4×	939 1.4×	110	2.3k
Vicki Rubin Kelley United States	38	835 0.6×	168 0.1×	2.8k 2.7×	263 0.4×	1.0k 1.6×	75	4.5k
Zhao Cui China	35	1.7k 1.2×	227 0.2×	661 0.6×	437 0.6×	807 1.2×	143	2.9k
Emmanuelle Plaisier France	25	924 0.7×	262 0.2×	162 0.2×	351 0.5×	623 0.9×	58	2.3k
Jon I. Scheinman United States	24	498 0.4×	458 0.4×	274 0.3×	504 0.7×	399 0.6×	48	2.0k
Patrizia Noris Italy	36	230 0.2×	2.2k 2.0×	314 0.3×	647 0.9×	300 0.5×	91	2.9k
Costanza Sagrinati Italy	16	884 0.6×	126 0.1×	642 0.6×	249 0.3×	1.6k 2.5×	19	3.0k
H. Terence Cook United Kingdom	22	994 0.7×	236 0.2×	824 0.8×	161 0.2×	370 0.6×	45	2.3k

Countries citing papers authored by Daniel P. Gale

Since Specialization

Citations

This map shows the geographic impact of Daniel P. Gale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel P. Gale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel P. Gale more than expected).

Fields of papers citing papers by Daniel P. Gale

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel P. Gale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel P. Gale. The network helps show where Daniel P. Gale may publish in the future.

Co-authorship network of co-authors of Daniel P. Gale

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel P. Gale. A scholar is included among the top collaborators of Daniel P. Gale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel P. Gale. Daniel P. Gale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sadeghi‐Alavijeh, Omid, Melanie Chan, Horia Stanescu, Daniel P. Gale, & Detlef Böckenhauer. (2025). Fifty Shades of Risk. Journal of the American Society of Nephrology. 37(2). 361–369.

Wu, Jingyi, Yuemiao Zhang, Zhao Zhang, et al.. (2025). B Cell-Specific Deletion of C1GALT1 Elevates Serum Gd-IgA1 but Fails to Induce Mesangial IgA Deposition in Humanized IGHA1 Mice. Journal of the American Society of Nephrology. 36(10S).

Pitcher, David, Fiona Braddon, Bruce M. Hendry, et al.. (2025). Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria. Journal of the American Society of Nephrology. 36(7). 1398–1413. 2 indexed citations

Gale, Daniel P., Andrew S. Bomback, Christoph Licht, et al.. (2025). #3391 Pegcetacoplan treatment appears to halt disease progression in C3G and primary (idiopathic) IC-MPGN patients: results from the phase 3 VALIANT study. Nephrology Dialysis Transplantation. 40(Supplement_3). 1 indexed citations

Sadeghi‐Alavijeh, Omid, Melanie Chan, Gabriel Doctor, et al.. (2024). Quantifying variant contributions in cystic kidney disease using national-scale whole-genome sequencing. Journal of Clinical Investigation. 134(19). 2 indexed citations

Voinescu, C, Monika Mozere, Giulio Genovese, et al.. (2024). A Neanderthal haplotype introgressed into the human genome confers protection against membranous nephropathy. Kidney International. 105(4). 791–798. 2 indexed citations

Deltas, Constantinos, Gregory Papagregoriou, Stavroula F. Louka, et al.. (2023). Genetic Modifiers of Mendelian Monogenic Collagen IV Nephropathies in Humans and Mice. Genes. 14(9). 1686–1686. 8 indexed citations

Reck, Martin, Ernest Nadal, Nicolas Girard, et al.. (2023). 115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC. Immuno-Oncology Technology. 20. 100587–100587. 1 indexed citations

Mercer, Alex, Kevin Carroll, Bruce M. Hendry, et al.. (2023). #4503 ESTIMATING DELAY IN TIME TO KIDNEY FAILURE OR DEATH FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY. Nephrology Dialysis Transplantation. 38(Supplement_1). 2 indexed citations

10.

Pitcher, David, Fiona Braddon, Bruce M. Hendry, et al.. (2023). Long-Term Outcomes in IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 18(6). 727–738. 169 indexed citations breakdown →

11.

Reck, Martin, Daniel P. Gale, David H. Harpole, et al.. (2023). LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. Annals of Oncology. 34. S1300–S1300. 23 indexed citations

12.

Morais, Mychel, Craig Lawless, Syed Murtuza Baker, et al.. (2022). Kidney organoids recapitulate human basement membrane assembly in health and disease. UCL Discovery (University College London). 28 indexed citations

13.

Lin, Fujun, Heena V. Lad, Francesca Mazzacuva, et al.. (2022). Tissue Proteome of 2-Hydroxyacyl-CoA Lyase Deficient Mice Reveals Peroxisome Proliferation and Activation of ω-Oxidation. International Journal of Molecular Sciences. 23(2). 987–987. 7 indexed citations

14.

Gor, Jayesh, et al.. (2020). The solution structure of the complement deregulator FHR5 reveals a compact dimer and provides new insights into CFHR5 nephropathy. Journal of Biological Chemistry. 295(48). 16342–16358. 1 indexed citations

15.

Gale, Daniel P., Andrew J. Mallett, Chirag Patel, et al.. (2020). Diagnoses of uncertain significance: kidney genetics in the 21st century. Nature Reviews Nephrology. 16(11). 616–618. 11 indexed citations

16.

Breno, Matteo, Nicolò Ghiringhelli Borsa, Fengxiao Bu, et al.. (2018). Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. The Journal of Immunology. 200(7). 2464–2478. 119 indexed citations

17.

Connor, Thomas M., Simon Hoer, Andrew J. Mallett, et al.. (2017). Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. PLoS Genetics. 13(3). e1006620–e1006620. 40 indexed citations

18.

Gale, Daniel P., Benjamin Rhodes, John Feehally, et al.. (2010). Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients (vol 25, pg 1547, 2010). UCL Discovery (University College London).

19.

Ashby, Damien, Daniel P. Gale, Mark Busbridge, et al.. (2009). Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney International. 75(9). 976–981. 250 indexed citations

20.

Lynch, et al.. (1974). Local experience in the treatment of acute non-lymphoblastic leukaemia.. PubMed. 48(22). 963–7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact